|
[1]
|
Duan AR,Goodson HV.Taxol-stabilized microtubules promote the formation of filaments from unmodified full-length Tau in vitro[J].Mol Biol Cell,2012,23(24):4796-4806. |
|
[2]
|
Sudo T,Nitta M,Saya H,et al.Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoin[J].Cancer Res,2004,64(7):2502-2508. |
|
[3]
|
Wertz IE,Kusam S,Lam C,et al.Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW[J].Nature,2011,471(7336):110-114. |
|
[4]
|
Blagosklonny MV,Fojo T.Molecular effects of paclitaxel:myths and reality(a critical review)[J].Int J Cancer,1999,83(2):151-156. |
|
[5]
|
Stearns ME,Wang M.Taxol blocks processes essential for prostate tumor cell(PC-3 ML) invasion and metastases[J].Cancer Res,1992,52(13):3776-3781. |
|
[6]
|
Adams JD,Flora KP,Goldspiel BR,et al.Taxol:a history of pharmaceutical development and current pharmaceutical concerns[J].J Natl Cancer Inst Monogr,1993(15):141-147. |
|
[7]
|
Singla AK,Garg A,Aggrawal D.Aggarwal,Paclitaxel and its formulations[J].Int J Pharm,2002,235(1/2):179-192. |
|
[8]
|
Weiss RB,Donehower RC,Wiernik PH,et al,Hypersensitivity reactions from taxo[J].J Clin Oncol,1990,8(7):1263-1268. |
|
[9]
|
Kim SC,Yoon HJ,Lee JW,et al.Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles[J].Int J Pharm,2005,293(1/2):303-310. |
|
[10]
|
Xu Q,Trissel LA,Martinez JF.Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4,22,or 32 degrees C[J].Am J Hosp Pharm,1994,51(24):3058-3060. |
|
[11]
|
Erez R,Segal E,Miller K,et al.Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel[J].Bioorg Med Chem,2009,17(13):4327-4335. |
|
[12]
|
Ye L,He J,Hu Z,et al.Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts[J].Food Chem Toxicol,2013,52:200-206. |
|
[13]
|
Nie S,Hsiao WL,Pan W,et al.Thermoreversible Pluronic F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel:in vitro drug release,cell cytotoxicity,and uptake studies[J].Int J Nanomedicine,2011,6:151-166. |
|
[14]
|
Bull JL.The application of microbubbles for targeted drug delivery[J].Expert Opin Drug Deliv,2007,4(5):475-493. |
|
[15]
|
Yan F,Li L,Deng Z,et al.Paclitaxel-liposome-microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers[J].J Control Release,2013,166(3):246-255. |
|
[16]
|
Wu J,Liu Q,Lee R J.A folate receptor-targeted liposomal formulation for paclitaxel[J].Int J Pharm,2006,316(1/2):148-153. |
|
[17]
|
Wang X,Deng L,Chen X,et al.Truncated bFGF-mediated cationic liposomal paclitaxel for tumor-targeted drug delivery:improved pharmacokinetics and biodistribution in tumor-bearing mice[J].J Pharm Sci,2011,100(3):1196-1205. |
|
[18]
|
Yang T,Choi MK,Cui FD,et al.Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome[J].J Control Release,2007,120(3):169-177. |
|
[19]
|
Peer D,Margalit R.Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models[J].Neoplasia,2004,6(4):343-353. |
|
[20]
|
Penno MB,August JT,Baylin J,et al.Expression of CD44 in human lung tumors[J].Cancer Res,1994,54(5):1381-1387. |
|
[21]
|
Rivkin I,Cohen K,Koffler J,et al.Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors[J].Biomaterials,2010,31(27):7106-7114. |
|
[22]
|
Yoshizawa Y,Kono Y,Ogawara K,et al.PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy[J].Int J Pharm,2011,412(1/2):132-141. |
|
[23]
|
Bode C,Trojan L,Weiss C,et al.Paclitaxel encapsulated in cationic liposomes:a new option for neovascular targeting for the treatment of prostate cancer[J].Oncol Rep,2009,22(2):321-326. |
|
[24]
|
Zhang JQ,Zhang ZR,Yang H,et al.Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration:in vitro and in vivo studies[J].Pharm Res,2005,22(4):573-583. |
|
[25]
|
Fonseca C,Simoes S,Gaspar R.Paclitaxel-loaded PLGA nanoparticles:preparation,physicochemical characterization and in vitro anti-tumoral activity[J].J Control Release,2002,83(2):273-286. |
|
[26]
|
Monsky WL,Fukumura D,Gohongi T,et al.Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor[J].Cancer Res,1999,59(16):4129-4135. |
|
[27]
|
Paal K,Muller J,Hegedus L.High affinity binding of paclitaxel to human serum albumin[J].Eur J Biochem,2001,268(7):2187-2191. |
|
[28]
|
Desai N,Trieu V,Yao Z,et al.Increased antitumor activity,intratumor paclitaxel concentrations,and endothelial cell transport of cremophor-free,albumin-bound paclitaxel,ABI-007,compared with cremophor-based paclitaxel[J].Clin Cancer Res,2006,12(4):1317-1324. |
|
[29]
|
Wang G,Yu B,Wu Y,et al.Controlled preparation and antitumor efficacy of vitamin E TPGS -functionalized PLGA nanoparticles for delivery of paclitaxe[J].l.Int J Pharm,2013,446(1/2):24-33. |
|
[30]
|
Smitha KT,Anitha A,Furuike T,et al.In vitro evaluation of paclitaxel loaded amorphous chitin nanoparticles for colon cancer drug delivery[J].Colloids Surf B Biointerfaces,2012,104:245-253. |
|
[31]
|
Xia H,Gu GZ,Hu QY,et al.Activatable cell penetrating peptide-conjugated nanoparticles with enhanced permeability for site-specific targeting delivery of anticancer drug[J].Bioconjug Chem,2013,24(3):419-430. |
|
[32]
|
Jia L,Shen J,Li Z,et al.In vitro and in vivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes[J].Int J Pharm,2013,445(1/2):12-19. |
|
[33]
|
Wang F,Zhang D,Zhang Q,et al.Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance[J].Biomaterials,2011,32(35):9444-9456. |
|
[34]
|
Gong C,Xie Y,Wu Q,et al.Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma[J].Nanoscale,2012,4(19):6004-6017. |
|
[35]
|
Tao Y,Han J,Wang X,et al.Nano-formulation of paclitaxel by vitamin E succinate functionalized pluronic micelles for enhanced encapsulation,stability and cytotoxicity[J].Colloids Surf B Biointerfaces,2013,102:604-610. |
|
[36]
|
Nuijen B,Bouma M,Schellens JH,et al.Progress in the development of alternative pharmaceutical formulations of taxanes[J].Invest New Drugs,2001,19(2):143-153. |
|
[37]
|
Mellado W,Magri NF,Kingston DG,et al.Preparation and biological activity of taxol acetates[J].Biochem Biophys Res Commun,1984,124(2):329-336. |
|
[38]
|
Vyas DM,Wong H,Crosswell AR,et al.Synthesis and antitumor evaluation of water soluble taxol phosphates[J].Bioorganic and Med Chem Lett,1993,36(13):1797-1801. |
|
[39]
|
Homsi J,Bedikian AY,Kim KB,et al.Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients[J].Melanoma Res,2009,19(4):238-242. |
|
[40]
|
Elsadek B,Graeser R,Esser N,et al.Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen:an in vitro and in vivo evaluation study[J].Eur J Cancer,2010,46(18):3434-3444. |
|
[41]
|
Terwogt JM,Nuijen B,Huinink WW,et al.Alternative formulations of paclitaxel[J].Cancer Treat Rev,1997,23(2):87-95. |
|
[42]
|
Heldman AW,Cheng L,Jenkins GM,et al.Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis[J].Circulation,2001,103(18):2289-2295. |
|
[43]
|
Dake MD,Van Alstine WG,Zhou Q,et al.Polymer-free paclitaxel-coated Zilver PTX Stents--evaluation of pharmacokinetics and comparative safety in porcine arteries[J].J Vasc Interv Radiol,2011,22(5):603-610. |
点击查看大图
下载:
